Latest Insights in Clinical Studies
Two abstracts published in The Journal of Urology.
Llusern Scientific was pleased that two abstracts assessing the Lodestar UTI testing panel in clinical settings were published in the…
New study data demonstrates Lodestar more accurate than lab culture
In an independent study undertaken at the Royal Berkshire Hospital, in September to October 2025, Lodestar was tested against the…
Llusern’s Lodestar DX Evaluation Published in JAC-AMR: Demonstrating High Correlation with Gold Standard UTI Testing
This peer-reviewed study explores the potential of Lodestar DX, utilising loop-mediated isothermal amplification (LAMP) technology, to rapidly and accurately diagnose…
UTI test undergoing clinical verification and validation
Llusern are pleased and proud to be working with the Bevan Commission to tackle the problem of UTIs. Llusern, in…
Start a conversation with Llusern
Llusern is developing treatment-directing diagnostics for high-volume healthcare challenges, starting with rapid molecular UTI testing. To learn more about the company, the product and the opportunity ahead, speak to the Llusern team.